We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
Read MoreHide Full Article
Key Takeaways
Lilly's oncology sales are projected at $2.58B for Q3 2025, up over 15% year over year.
Verzenio demand and pricing gains are expected to drive growth despite currency and competition.
New drug Inluriyo won FDA approval but will not contribute sales until post-Q3 launch.
While Eli Lilly (LLY - Free Report) is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro and Zepbound (for obesity), the company also generates a meaningful portion of revenues from its oncology franchise. Sales from the oncology drugs accounted for more than 15% of Lilly’s first-half 2025 revenues, which grew about 10% year over year.
Our model estimates that third-quarter 2025 sales for the overall oncology unit will be $2.58 billion, representing over 15% year-over-year growth. A significant portion of these revenues is likely to be generated from sales of the company’s blockbuster breast cancer drug, Verzenio. Sales of this drug are expected to have been driven by increased demand and higher realized prices during the period, partially offset by currency headwinds and competitive dynamics.
Sales of RET inhibitor Retevmo and the newer lymphoma drug Jaypirca are also expected to contribute positively to top-line growth during the quarter. However, these gains are likely to have been partially offset by lower sales of older cancer drugs like Alimta and Cyramza, which are being impacted by competition from immuno-oncology agents in the United States.
Though Lilly secured FDA approval for its new breast cancer drug, Inluriyo, in late September, it indicated that the launch would occur in “the coming weeks.” As such, we do not expect the company to generate any sales from the drug in the third quarter.
As markets await another strong quarter from Lilly’s GLP-1 portfolio, attention may gradually shift toward the company’s oncology unit, which is showing consistent double-digit growth. This could help reassure investors that Lilly’s earnings trajectory isn’t solely tied to the obesity segment ahead of the Q3 results on Oct. 30.
For AstraZeneca, oncology sales now account for nearly 43% of total revenues. Sales in its oncology segment rose 11% in the first half of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 48% of Merck’s total revenues in the first half of 2025.
Pfizer’s first-half 2025 oncology revenues grew 9% on an operational basis, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. The segment now accounts for over 25% of Pfizer’s overall sales.
LLY’s Price Performance, Valuation and Estimates
Shares of Lilly have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 27.99 times forward earnings, higher than its industry’s average of 15.56. However, the stock is trading below its five-year mean of 34.54.
Image Source: Zacks Investment Research
EPS estimates for 2025 have declined from $23.15 to $22.86, while those for 2026 have decreased from $30.82 to $30.78 over the past 30 days.
Image: Bigstock
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
Key Takeaways
While Eli Lilly (LLY - Free Report) is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro and Zepbound (for obesity), the company also generates a meaningful portion of revenues from its oncology franchise. Sales from the oncology drugs accounted for more than 15% of Lilly’s first-half 2025 revenues, which grew about 10% year over year.
Our model estimates that third-quarter 2025 sales for the overall oncology unit will be $2.58 billion, representing over 15% year-over-year growth. A significant portion of these revenues is likely to be generated from sales of the company’s blockbuster breast cancer drug, Verzenio. Sales of this drug are expected to have been driven by increased demand and higher realized prices during the period, partially offset by currency headwinds and competitive dynamics.
Sales of RET inhibitor Retevmo and the newer lymphoma drug Jaypirca are also expected to contribute positively to top-line growth during the quarter. However, these gains are likely to have been partially offset by lower sales of older cancer drugs like Alimta and Cyramza, which are being impacted by competition from immuno-oncology agents in the United States.
Though Lilly secured FDA approval for its new breast cancer drug, Inluriyo, in late September, it indicated that the launch would occur in “the coming weeks.” As such, we do not expect the company to generate any sales from the drug in the third quarter.
As markets await another strong quarter from Lilly’s GLP-1 portfolio, attention may gradually shift toward the company’s oncology unit, which is showing consistent double-digit growth. This could help reassure investors that Lilly’s earnings trajectory isn’t solely tied to the obesity segment ahead of the Q3 results on Oct. 30.
Competition in the Oncology Space
Other bigger players in this area include AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
For AstraZeneca, oncology sales now account for nearly 43% of total revenues. Sales in its oncology segment rose 11% in the first half of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 48% of Merck’s total revenues in the first half of 2025.
Pfizer’s first-half 2025 oncology revenues grew 9% on an operational basis, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. The segment now accounts for over 25% of Pfizer’s overall sales.
LLY’s Price Performance, Valuation and Estimates
Shares of Lilly have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 27.99 times forward earnings, higher than its industry’s average of 15.56. However, the stock is trading below its five-year mean of 34.54.
Image Source: Zacks Investment Research
EPS estimates for 2025 have declined from $23.15 to $22.86, while those for 2026 have decreased from $30.82 to $30.78 over the past 30 days.
Image Source: Zacks Investment Research
Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.